On June 13th, Gelonhui reported that Huiyu Pharmaceuticals (688553.SH) announced that its wholly-owned subsidiary, Seacross Pharma (Europe) Ltd., recently received approval from the French National Agency for Medicines and Health Products Safety for the marketing of its product, Setipar. Setipar is used in combination with other chemotherapy drugs for pre-treatment of adult and pediatric patients with allogeneic or autologous hematopoietic progenitor cell transplantation (HPCT), with or without total body radiation (TBI). When high-dose chemotherapy supported by HPCT is appropriate, the product can be used to treat various solid tumors in adult and pediatric patients.
汇宇制药(688553.SH)：注射用赛替派获得法国上市许可
Huayu Pharmaceutical (688553.SH): Injection-based Saitipai has obtained market approval in France.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.